Agios Pharmaceuticals (AGIO) Enterprise Value (2016 - 2025)
Agios Pharmaceuticals (AGIO) has disclosed Enterprise Value for 13 consecutive years, with -$854.4 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value rose 4.4% year-over-year to -$854.4 million, compared with a TTM value of -$854.4 million through Dec 2025, up 4.4%, and an annual FY2025 reading of -$854.4 million, up 4.4% over the prior year.
- Enterprise Value was -$854.4 million for Q4 2025 at Agios Pharmaceuticals, up from -$952.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$569.9 million in Q2 2024 and bottomed at -$2.3 billion in Q1 2021.
- Average Enterprise Value over 5 years is -$956.0 million, with a median of -$873.9 million recorded in 2025.
- The sharpest move saw Enterprise Value crashed 341.83% in 2021, then soared 60.46% in 2022.
- Year by year, Enterprise Value stood at -$1.0 billion in 2021, then grew by 23.22% to -$783.1 million in 2022, then increased by 0.79% to -$776.9 million in 2023, then fell by 15.03% to -$893.7 million in 2024, then rose by 4.4% to -$854.4 million in 2025.
- Business Quant data shows Enterprise Value for AGIO at -$854.4 million in Q4 2025, -$952.9 million in Q3 2025, and -$938.9 million in Q2 2025.